A phase I and pharmacokinetic study of intraperitoneal topotecan

Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan. Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were treated with escalating IP topotecan doses (5–30 mg/m(2)) for pharmacokinetic analysis. Results: Dose limiting toxicit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hofstra, L S, Bos, A M E, Vries, E G E de, Zee, A G J van der, Beijnen, J H, Rosing, H, Mulder, N H, Aalders, J G, Willemse, P H B
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2001
Schlagworte:
Regular Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2363984/
https://ncbi.nlm.nih.gov/pubmed/11742479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2001.2161
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge